Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1237Docetaxel 1227Oxaliplatin 1184Capecitabine 1176Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 639Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × regadenoson × Clear all
NCT03505736 2026-01-29

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

Wake Forest University Health Sciences

Completed
25 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡